1. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. (23rd February 2018) Authors: Italiano, A; Infante, J R; Shapiro, G I; Moore, K N; LoRusso, P M; Hamilton, E; Cousin, S; Toulmonde, M; Postel-Vinay, S; Tolaney, S; Blackwood, E M; Mahrus, S; Peale, F V; Lu, X; Moein, A; Epler, J; DuPree, K; Tagen, M; Murray, E R; Schutzman, J L Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗